Opko acquires early stage digital inhaler device co. to pair it with respiratory drugs

Featured Story

Opko acquires early stage digital inhaler device co. to pair it with respiratory drugs

April 17, 2014 3:00 pm by | 0 Comments

As pharmaceutical companies look for ways to add value to their drugs to solve problems like adherence, many see digital health as an important part of that strategy. Respiratory drug…


Mobile health apps from EHR to diabetes picked as Webby award honorees

Mobile health apps from EHR to diabetes picked as Webby award honorees

April 18, 2014 5:54 pm by | 0 Comments

As part of the annual Webby Awards this year,  11 mobile health apps were chosen as honorees. They include behavioral health apps from the Veteran’s Administration, a diabetes app from…


ASCO at work on a scoring system to weigh cost vs. potential benefits of pricey cancer treatments

ASCO at work on a scoring system to weigh cost vs. potential benefits of pricey cancer treatments

April 17, 2014 12:03 pm by | 0 Comments

Cancer doctors and patients need a better way to weigh the potential benefits of new targeted cancer treatments against their costs, especially those that carry a price tag north of…



Google pitches pharma on YouTube merits for DtC advertising

Google pitches pharma on YouTube merits for DtC advertising

April 17, 2014 11:38 am by | 0 Comments

The pharmaceutical industry is warming up to direct to consumer advertising on YouTube, but Google, which acquired the media channel in 2006, would like drug companies to get a lot warmer.


Space institute funds eye tracking to detect brain injury, drugs + apps platform

Space institute funds eye tracking to detect brain injury, drugs + apps platform

April 17, 2014 6:00 am by | 0 Comments

The National Space Biomedical Research Institute in Houston said it’s provided funding to two promising early-stage technologies that take novel approaches to problems both on earth and in space. First…


Zogenix prevails in initial challenge to Massachusetts emergency order banning ZOHYDRO ER

Zogenix prevails in initial challenge to Massachusetts emergency order banning ZOHYDRO ER

April 17, 2014 12:59 am by | 0 Comments

 By Kurt R. Karst –   When we first heard about the Complaint and Motion for Preliminary Injunction Zogenix, Inc. filed against Massachusetts Governor Deval Patrick, among others, alleging that…


One reason to embrace shift away from healthcare’s fee-for-service model: Better drugs

One reason to embrace shift away from healthcare’s fee-for-service model: Better drugs

April 16, 2014 10:09 pm by | 1 Comments

As much as people have been talking about the upcoming shift away from the fee-for-service model of healthcare, in most cases it’s an abstract concept as it’s still years away…


Teva recalls generic version of anti-depressant Cymbalta

Teva recalls generic version of anti-depressant Cymbalta

April 16, 2014 5:02 pm by | 0 Comments

“FiercePharmaManufacturing” reports that Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has recalled its generic version of anti-depressant Cymbalta, duloxetine, because of a customer complaint about capsule breakage. The voluntary…



Is this the ideal patient-payer-pharma social media convergence?

Is this the ideal patient-payer-pharma social media convergence?

April 16, 2014 4:38 pm by | 0 Comments

One of the dominant themes at the Eye for Pharma conference this week has been how pharmaceutical companies can use social media channels beyond just conveying a positive message about…


FDA makes adverse drug event data public, but this health IT startup makes it useful

FDA makes adverse drug event data public, but this health IT startup makes it useful

April 16, 2014 3:26 pm by | 0 Comments

Four times a year, the FDA releases data about all of the adverse drug events that have been reported to the agency over a three-month time period. Drug companies are…


Abbott earnings fall in 1Q as sales lag

Abbott earnings fall in 1Q as sales lag

April 16, 2014 1:34 pm by | 0 Comments

Abbott Laboratories said Wednesday its first-quarter profit fell 31.1 percent to $375 million, or 24 cents a share, as certain one-time costs, including expenses associated with repatriating international profits, ate…


If everyone has so many ‘solutions,’ why hasn’t anything in healthcare been solved yet?

If everyone has so many ‘solutions,’ why hasn’t anything in healthcare been solved yet?

April 16, 2014 12:16 pm by | 1 Comments

Neil Versel Twitter LinkedIn MidAmerica Healthcare Venture Forum, to take place April 22-23 in Chicago, unites active investors with corporate business development executives to facilitate investment opportunities with promising Mid-America…


Healthcare writer Bruce Japsen watching transformation of coverage in private, public sectors

Healthcare writer Bruce Japsen watching transformation of coverage in private, public sectors

April 16, 2014 12:10 pm by | 0 Comments

Bruce Japsen Twitter LinkedIn MidAmerica Healthcare Venture Forum, to take place April 22-23 in Chicago, unites active investors with corporate business development executives to facilitate investment opportunities with promising Mid-America…


Mayo’s James A. Rogers: It’s a great time for startups

Mayo’s James A. Rogers: It’s a great time for startups

April 16, 2014 11:56 am by | 0 Comments

James A. Rogers Twitter LinkedIn MidAmerica Healthcare Venture Forum, to take place April 22-23 in Chicago, unites active investors with corporate business development executives to facilitate investment opportunities with promising…


True Grit: Why pharma’s leaders aren’t yet capable

True Grit: Why pharma’s leaders aren’t yet capable

April 16, 2014 6:00 am by | 0 Comments

Faced with an ever-challenging commercial environment, how do upcoming pharma leaders stack up when it comes to critical leadership capabilities and how can they be nurtured to achieve success? “The…


Q&A with John Castellani of PhRMA

Q&A with John Castellani of PhRMA

April 15, 2014 3:57 pm by | 0 Comments

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading biopharmaceutical research and biotechnology companies. Dialogues+ had the opportunity to ask John Castellani, President and CEO of PhRMA, questions about his organization and the Physician Payments Sunshine Act….